BeiGene, Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
231.49
-4.45 (-1.89%)
May 9, 2025, 3:39 PM - Market open
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
| Collaboration | 30.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration Growth | -88.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Product | 3.78B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Product Growth | 72.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| REVLIMID | 36.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| REVLIMID Growth | -52.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| VIDAZA | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| VIDAZA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ABRAXANE | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ABRAXANE Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BRUKINSA | 2.64B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BRUKINSA Growth | 104.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tislelizumab | 620.84M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tislelizumab Growth | 15.69% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| XGEVA | 224.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| XGEVA Growth | 141.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product | 60.04M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Growth | 38.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BLINCYTO | 74.33M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BLINCYTO Growth | 36.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| POBEVCY | 53.51M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| POBEVCY Growth | -5.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pamiparib | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| KYPROLIS | 66.17M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| KYPROLIS Growth | 66.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
| U.S. | 1.96B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Growth | 73.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 1.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | 28.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 362.63M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | 79.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World | 78.81M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Growth | 166.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|